Preclinical and clinical studies have demonstrated the efficacy of anti-TROP2 antibody–drug conjugates (ADCs), such as sacituzumab govitecan (IMMU-132), an anti-TROP2 humanized antibody-SN-38 conjugate for cancer treatment (6, 7). The gene discussed is TACSTD2; the disease is cancer.